19:34 , Oct 19, 2018 |  BC Week In Review  |  Clinical News

BioLineRx reports response, survival data for BL-8040, Keytruda combo in pancreatic cancer

BioLineRx Ltd. (Tel Aviv:BLRX; NASDAQ:BLRX) reported data from the Phase IIa COMBAT/KEYNOTE-202 trial showing that BL-8040 plus Keytruda pembrolizumab led to a disease control rate (DCR) of 34.5%, including one partial response and nine cases...
21:53 , Jan 5, 2018 |  BC Week In Review  |  Clinical News

BioLineRx reports additional Phase IIa data for BL-8040 in AML

BioLineRx Ltd. (Tel Aviv:BLRX; NASDAQ:BLRX) reported data from the expansion portion of a Phase IIa trial in 16 patients with relapsed or refractory acute myelogenous leukemia (AML) showing that BL-8040 as monotherapy for two days...
17:45 , Aug 10, 2017 |  BC Week In Review  |  Clinical News

Genentech starts Phase Ib/II evaluating immunotherapy-based combos for pancreatic ductal adenocarcinoma

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) began an open-label, international Phase Ib/II trial to evaluate multiple immunotherapy-based combinations with PD-L1 inhibitor Tecentriq atezolizumab (MPDL3280A, RG7446) compared to chemotherapy with gemcitabine plus Abraxane nab-paclitaxel...
21:51 , Feb 9, 2017 |  BC Week In Review  |  Clinical News

BL-8040: Ph II started

BioLineRx said the University of Texas MD Anderson Cancer Center began an open-label, U.S. Phase II trial to evaluate subcutaneous 1.25 mg/kg BL-8040 plus 200 mg IV Keytruda pembrolizumab in about 15 patients. Patients will...
07:00 , Sep 26, 2016 |  BC Week In Review  |  Clinical News

BL-8040: Phase IIa started

BioLineRx began the open-label, international Phase IIa COMBAT trial to evaluate 1.25 mg/kg subcutaneous BL-8040 with or without Keytruda pembrolizumab in up to 30 patients. In January, BioLineRx partnered with Merck & Co. Inc. (NYSE:MRK,...
07:00 , Sep 12, 2016 |  BC Week In Review  |  Company News

BioLineRx, Genentech, Roche deal

BioLineRx and Roche’s Genentech unit partnered to conduct Phase Ib trials evaluating BioLineRx’s BL-8040 plus Genentech’s Tecentriq atezolizumab. Genentech will conduct several trials in solid cancers, and BioLineRx will conduct a single trial in acute...
07:00 , Apr 4, 2016 |  BC Week In Review  |  Clinical News

BL-8040: Additional Phase IIa data

Data from 39 patients with relapsed or refractory AML in an open-label, U.S. and Israeli Phase IIa trial showed that once-daily 1-2 mg/kg subcutaneous BL-8040 as monotherapy on days 1 and 2 followed by BL-8040...
07:00 , Mar 28, 2016 |  BC Week In Review  |  Clinical News

BL-8040: Phase II started

BioLineRx began an open-label, U.S. Phase II trial to evaluate subcutaneous BL-8040 in about 24 donor/recipient pairs. Donors will receive BL-8040 followed by leukapheresis on day 1 to reach >=5x10 6 CD34+ cells/kg. If the...
08:00 , Dec 14, 2015 |  BC Week In Review  |  Clinical News

BL-8040: Phase I/II started

BioLine began an open-label, U.S. Phase I/II trial to evaluate subcutaneous BL-8040 plus standard immunotherapy in up to 25 patients. Patients will receive 0.75 mg/kg BL-8040 on days 1-10, then on the first 5 days...
07:00 , Sep 28, 2015 |  BC Week In Review  |  Clinical News

BL-8040: Phase IIb started

BioLineRx began the double-blind, placebo-controlled, German Phase IIb BLAST trial to evaluate 1.25 mg/kg subcutaneous BL-8040 once daily on days 1-5 plus twice-daily IV cytarabine on days 1, 3 and 5 of each 28-day cycle...